Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 14;2(2):354-79.
doi: 10.3390/vaccines2020354.

HIV DNA Vaccine: Stepwise Improvements Make a Difference

Barbara K Felber  1 , Antonio Valentin  2 , Margherita Rosati  3 , Cristina Bergamaschi  4 , George N Pavlakis  5
Affiliations
Review

HIV DNA Vaccine: Stepwise Improvements Make a Difference

Barbara K Felber et al. Vaccines (Basel). .

Abstract

Inefficient DNA delivery methods and low expression of plasmid DNA have been major obstacles for the use of plasmid DNA as vaccine for HIV/AIDS. This review describes successful efforts to improve DNA vaccine methodology over the past ~30 years. DNA vaccination, either alone or in combination with other methods, has the potential to be a rapid, safe, and effective vaccine platform against AIDS. Recent clinical trials suggest the feasibility of its translation to the clinic.

Keywords: DNA delivery; DNA expression; cytokine; electroporation; immunogenicity; macaque; plasmid; vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Optimization of DNA expression and delivery: from bench to bedside. Several steps are necessary to improve the efficiency of DNA as vaccine including RNA/codon optimization of the gene, the use of optimized expression vectors, and combinations of DNA vaccine with molecular adjuvants to increase immunogenicity and using different delivery methods and sites.
See this image and copyright information in PMC

References

    1. Berman P.W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses. 1998;14:S277–S289. - PubMed
    1. Francis D.P., Gregory T., McElrath M.J., Belshe R.B., Gorse G.J., Migasena S., Kitayaporn D., Pitisuttitham P., Matthews T., Schwartz D.H., et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res. Hum. Retroviruses. 1998;14:S325–S331. - PubMed
    1. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006;194:1661–1671. doi: 10.1086/508748. - DOI - PubMed
    1. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005;191:654–665. doi: 10.1086/428404. - DOI - PubMed
    1. McElrath M.J., de Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: A case-cohort analysis. Lancet. 2008;372:1894–1905. doi: 10.1016/S0140-6736(08)61592-5. - DOI - PMC - PubMed